drugset / Trial / NCT00414765

Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

NCT00414765

Phase 4 Completed 26 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study evaluated the pharmacokinetics of aldesleukin in participants with metastatic renal cell cancer or metastatic melanoma.

Timeline

Start
2008-09-03
Primary completion
2010-03-28
Completion
2010-03-28

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic 600000 iu/kg Intravenous